Thermo Fisher Scientific Inc. Stock Borsa Italiana

Equities

4TMO

US8835561023

Advanced Medical Equipment & Technology

Real-time Estimate Tradegate 07:27:11 2024-07-12 am EDT 5-day change 1st Jan Change
499.1 EUR -0.74% Intraday chart for Thermo Fisher Scientific Inc. +2.39% +4.34%
Sales 2024 * 43.01B 39.5B Sales 2025 * 46.04B 42.27B Capitalization 207B 190B
Net income 2024 * 6.18B 5.68B Net income 2025 * 6.96B 6.39B EV / Sales 2024 * 5.36 x
Net Debt 2024 * 23.2B 21.3B Net Debt 2025 * 19.14B 17.57B EV / Sales 2025 * 4.92 x
P/E ratio 2024 *
33.9 x
P/E ratio 2025 *
29.1 x
Employees 122,000
Yield 2024 *
0.27%
Yield 2025 *
0.3%
Free-Float 86.04%
More Fundamentals * Assessed data
Dynamic Chart
Thermo Fisher Scientific Keeps Quarterly Cash Dividend at $0.39 Per Share, Payable Oct. 15 to Holders as of Sept. 13 MT
Thermo Fisher Scientific Inc. Declares Quarterly Cash Dividend, Payable on October 15, 2024 CI
Thermo Fisher Scientific to Work With National Cancer Institute to Advance Research on New Treatments MT
Thermo Fisher Scientific to Help Advance Myeloid Cancer Clinical Research and Treatment Utilizing Next Generation Sequencing Technology CI
Thermo Fisher Scientific Completes Acquisition of Olink MT
Thermo Fisher Scientific Inc. completed the acquisition of Olink Holding AB from Summa Equity AB and others. CI
Thermo Fisher Scientific Opens Its First Electron Microscopy Demo Center in Taiwan CI
Olink Holding Receives UK Approval for Thermo Fisher's $26 per Share Tender Offer MT
UK Competition Watchdog Clears Thermo Fisher Scientific's Purchase of Sweden's Olink MT
UK's competition regulator clears $3.1 billion Thermo Fisher Scientific-Olink deal RE
Evercore ISI Cuts Price Target on Thermo Fisher Scientific to $600 From $615, Maintains Outperform Rating MT
Verici Dx hails milestone payment in deal with Thermo Fisher AN
Thermo Fisher Scientific Inc.(NYSE:TMO) dropped from Russell Top 200 Growth Index CI
Thermo Fisher Scientific Inc.(NYSE:TMO) dropped from Russell 3000 Growth Index CI
Thermo Fisher Scientific Inc.(NYSE:TMO) dropped from Russell 3000E Growth Index CI
More news
1 day-0.74%
1 week+2.39%
Current month-2.80%
1 month-6.47%
3 months-6.04%
6 months+1.31%
Current year+4.34%
More quotes
1 week
490.10
Extreme 490.1
502.80
1 month
490.10
Extreme 490.1
532.80
Current year
489.20
Extreme 489.2
551.40
1 year
401.90
Extreme 401.9
551.40
3 years
401.90
Extreme 401.9
591.90
5 years
243.70
Extreme 243.7
591.90
10 years
243.70
Extreme 243.7
591.90
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 01-10-31
Director of Finance/CFO 57 01-05-31
Chief Tech/Sci/R&D Officer - 18-12-31
Members of the board TitleAgeSince
Chief Executive Officer 56 01-10-31
Director/Board Member 67 12-03-29
Director/Board Member 62 22-02-28
More insiders
Date Price Change
24-07-10 502.8 +2.52%
24-07-10 490.4 +0.07%
24-07-09 490.1 -1.30%
24-07-08 496.6 -0.11%
24-07-05 497.1 +1.23%

End-of-day quote Borsa Italiana, July 10, 2024

More quotes
Thermo Fisher Scientific Inc. specializes in the design, manufacturing and marketing of laboratory and scientific equipments. Net sales (including intragroup) break down by family of products as follows: - laboratory equipments (70%). Moreover, the group proposes chemical products (reagents, solvent, salts, etc.), consumable products (tubes, funnels, vials, etc.), as well as conditioning, warehousing, storage, etc.; - diagnostics equipment and products (15.3%); - scientific analysis equipments (14.7%): analyzer (of water, gas, grounds, etc.), mass spectrometers, molecular spectroscopes, microscopes, manometers, samplers, microbiology equipments, reactive agents, etc. Net sales break down by source of income into products sales (78.5%) and services (21.5%). Net sales break down geographically as follows: North America (53%), Europe (25.7%), Asia-Pacific (18.1%) and others (3.2%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
542.7 USD
Average target price
628.2 USD
Spread / Average Target
+15.76%
Consensus